Marijuana Nation – Dr. Raphael Mechoulam.

Author: Joe Smith  /  Category: GW PHARMACEUTICALS

National Geographic Explorer: Marijuana Nation – Dr. Raphael Mechoulam Marijuana is used medicinally to fight cancer, chronic pain, spasticity from multiple sclerosis, nausea and vomiting in HIV patients, as well as the nausea and vomiting associated with chemotherapy. As with any medicine, if properly used it has many benefits. It can even be used topically to stop some skin cancers. THC is proven to stop the most aggressive cancer in human brain cells. GWPharma – Sativex (MMJ) is in clinical trials. Science is indisputable, human behavior is not.

Cannabis Science Reports Its First Documentary Release Date of April 5, 2012 “CHRONIC FUTURE – KILLING CANCER” A DOCUMENTARY ABOUT THE TRUTH AND BENEFITS OF MEDICAL MARIJUANA

Author: Joe Smith  /  Category: Cannabis Science, Inc.

Cannabis Science Reports Its First Documentary Release Date of April 5, 2012 “CHRONIC FUTURE – KILLING CANCER” A DOCUMENTARY ABOUT THE TRUTH AND BENEFITS OF MEDICAL MARIJUANA

March 27, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB:CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is thrilled to announce that Muse Productions out of SCOTTSDALE, Arizona – announced today the Premier date of CHRONIC FUTURE – KILLING CANCER. The first of many Documentaries’ centering on the successful cancer treatments Cannabis Science has been reporting.

CHRONIC FUTURE – KILLING CANCER will premier on April 5th, 2012, at the Harkins Theater on Shea and Scottsdale Road in Scottsdale. Media are invited to the 5:00pm airing (limited seating) with a Q & A to follow. A VIP airing will start at 7:00pm. CHRONIC FUTURE will remain in rotation through the month of April at this Harkins Theater.

CHRONIC FUTURE is a documentary created by Henry Miller and Cory Pritchard. It tells the story of Arizona’s Governor, Janet Brewer’s attempt to close down medical marijuana dispensaries and Allan Sobol, along with advocate attorney Tom Dean, fight to keep them. After the win in court, the story continues as it introduces patient after patient with debilitating ailment where medical marijuana healing ingredients have successfully treated the disease.

Perhaps the biggest revolution to this story is the apparent success and healing power that cannabis has when used to treat cancer patients. Cannabis Science (NASD OTCBB: CBIS) is a pioneering US biotech company that is developing pharmaceutical cannabis products. Cannabis Science has worked with 4 patients who administered Cannabis Science approved extracts to self-treat basal cell and squamous cell carcinomas (skin cancer).

The film covers everything from seed to success in the political and medical arena. As the unfortunate dark side the film also illuminates and exposes the story of how the government has avoided and covered up the successful medicinal use of marijuana, and decades of hypocrisy and misdirected messaging.

Photo-documentation on the Cannabis Science website (www.cannabisscience.com), shows that concentrated marijuana extract, topically applied to skin cancer, dramatically reduces the tumor burden and in some cases appears to have eliminated the cancer as confirmed by biopsy.

Dr. Melamede comments, “Chronic Future is a very important film. It highlights the extent to which prohibitionists are willing to impede the voice of American Citizens as expressed at the ballot box. How is it possible that our representatives in the various levels of government are allowed to get away actions that are undemocratic, and in fact treasonous. The documentary should outrage every American.”

The objective of the CHRONIC FUTURE documentary is to tell the truth about the benefits of medical marijuana, the government cover-up, and through the power of the media, reverse the negative stigma and propaganda the government has instilled in the public since the 1930s.

About Muse Productions:
Muse Productions is headed by Henry Miller. During the last six years of running his logistic company he wrote 35 script as well as wrote and directed three short films, one of which, “Rollers” won at the New York Film Festival.

Other projects of Muse Productions include a full feature film “Fix” about the rise and fall of a rock star featuring music from Guns and Roses, and “The Black Angels.”

About Dr Robert Melamede, PH.D:
Dr. Robert Melamede is the President & CEO of Cannabis Science Inc. and Associate Professor of Biology, University of Colorado, Colorado Springs, in one of the eleven states that allow the medicinal use of marijuana. Dr. Melamede is an expert on the biology of the cannabis plant, how it relates to the human endocannabinoid system, and why the cannabis plant has the potential to affect so many diseases and illnesses. Dr. Robert Melamede received his Ph.D. from the City University of NewYork. From there he became a Research Associate and Research Assistant Professor at New York Medical College and in 1989 he became a Research Assistant Professor at the University of Vermont. In 2001 he moved to the University of Colorado at Colorado Springs as an Associate Professor, and became the Chairman of the Biology Department until he retired as Chairman in the Fall of 2005. Dr. Melamede’s expertise has been the repair of DNA damages caused by free radicals, the production of monoclonal antibodies via phage display, far from equilibrium thermodynamics as applied to biological systems, and pulling these all together, the endocannabinoid system. Additionally, Dr. Melamede is a founder of a small biotech company (Newellink) exploring novel cancer therapies.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. Our formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science, Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
Investor Relations Management
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com
or
Hank Miller
Muse Entertainment
480-678-7728

View full post on News Releases

NO To Legal Marijuana – The Price Of Good Morals

Author: Joe Smith  /  Category: GW PHARMACEUTICALS

Californians will soon know it. It could cost the state 40000 released prisoners, 50000 teachers and no firefighters. Plus a lot of taxpayer money for prosecution of pot users. And that drug war in Mexico… will stay there, right? Surely these precautions have exterminated weed smokers, which generate a mere 14 billion dollar industry. Illegal, that is. Except the ones that already have medical marijuana cards. Funny how fast that other industry is growing. Along with the number of Medical Pot Companies… MEDICAL MARIJUANA (Public, PINK:MJNA) Cannabis Medical Solutions, Inc. (OTC:CMSI) Cannabis Science, Inc. (OTC:CBIS) GreenGro Technologies, Inc. (PINK:GRNH) GW Pharmaceuticals Plc. (PINK:GWPRF) Marijuana, Inc. (formerly Preachers Coffee Inc) (PINK:PCIO) Pharmos Corp. (PINK:PARS) Health Sciences Group, Inc. (PINK:HESG) Rapid Fire Marketing, Inc. (PINK:RFMK) Smokefree Innotec, Inc. (PINK:SFIO) Amergence Group, Inc.(AMNG) And as the saying goes… “It’s not a matter of if, but when”

Big Pharma Set to Take Over Medical Marijuana Market

Author: Joe Smith  /  Category: GW PHARMACEUTICALS

Daily News @ RevolutionNews.US — (RAW STORY) Just as the federal government is clamping down on medical marijuana dispensaries, the Federal Drug Administration (FDA) may be set to give Big Pharma the clearance to take over the market. In 2007, GW Pharmaceuticals announced that it partnered with Otsuka to bring “Sativex” — or liquefied marijuana — to the US The companies recently completed Phase II efficacy and safety trials testing and began discussion with the FDA for Phase III testing. Phase III is generally thought to be the final step before the drug can be marketed in the US “GW Pharmaceuticals plc (AIM GWP) today announces the initiation of the Phase III clinical trials programme of Sativex in the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy,” GW said in a statement. “This indication represents the initial target indication for Sativex in the United States.” Sativex is the brand name for a drug derived from cannabis sativa. It’s an extract from the whole plant cannabis, not a synthetic compound. Even GW defines the drug (.pdf) as marijuana. Yet as the FDA is poised to approve the drug for Big Pharma, state-licensed medical marijuana dispensaries that provide relief for thousands of Americans are under attack by other federal agencies. Full Article: www.rawstory.com — “Leave no authority existing not responsible to the people.” —Thomas Jefferson Time For A New American Revolution

Cannabis Science Reports: Three Former Federal Law Enforcement Agents Want To Legalize Marijuana Through Washington State Initiative 502

Author: Joe Smith  /  Category: Cannabis Science, Inc.

Cannabis Science Reports: Three Former Federal Law Enforcement Agents Want To Legalize Marijuana Through Washington State Initiative 502

December 19, 2011

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB: CBIS.OB – News) a pioneering US biotech company developing pharmaceutical cannabis products, is very pleased to report that two former US Attorneys, and the former head of Seattle FBI, are in favor of Washington State Initiative 502 to legalize marijuana.

On Seattle television King 5 News, two former US attorneys, John McKay and Kate Pflaumer and the former head of Seattle FBI, Charles Mandigo, spoke out on why they think it’s time to change the federal law and to legalize of marijuana.

Pflaumer stated, “It’s a policy position that has become obvious to me over 35 years working in criminal law enforcement and criminal law defense.”

Even though both US attorneys agree that it’s a bad policy, they said it was their job to enforce the law.

Former head of Seattle FBI, Charles Mandigo says he does not condone the use of marijuana, but he supports the initiative, because he feels strongly that the illegal drug trade and the resulting violence is destroying to our society.

Please visit:
http://www.king5.com/news/up-front/Is-it-time-to-legalize-marijuana-135827158.html.

And below to view the interviews in their entirety:

http://www.king5.com/news/up-front/video-extra/Up-Front-Extra-After-the-marijuana-interview-135776533.html.

State laws vary greatly, but under Federal law cultivation, possession, or sale of any amount, for any purpose, remain illegal. Washington State’s Initiative 502 would allow persons 21 and over to have in their possession either 1 ounce of dried marijuana, 16 ounces of marijuana infused food, or 72 ounces in a liquid form. The state’s Liquor Control Board would manage the system and the estimated income could be over $215 million per year. The state’s DUI laws would be extended to cover driving under the influence of marijuana.

Regarding concerns that the taxes being imposed would so high that this new law would not end the black market for sales, Mandigo replied, “I don’t think that’s the case, I think that most American people want to be law abiding, and given an opportunity to purchase marijuana in a regulated scheme, and not violate the law, that they would choose that as an option. Further if you are selling it under a regulated scheme, you have quality control and you know exactly what the substance is that is being sold and… at a regulated point-of-sale, that you can impose warning labels like you do for the sale of alcohol or tobacco.”

Some people fear that legalization might lead to marijuana becoming available in other places such as grocery stores, as did alcohol. Former US Attorney John McKay said, “The question is whether we should continue criminal prohibition of marijuana… for any amount for any reason. Is that successful? I don’t think so. We have a huge number of persons who smoke marijuana and obtain it illegally and the proceeds go to drug cartels. Better for us to look now at a scheme that we regulate, that we tax, and maintain criminal penalties.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Robert Kane, 1-561-234-6929
Investor Relations Management
info@cannabisscience.com
www.cannabisscience.com or
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases